Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
08 February 2025
Name: | BIONOMICS LIMITED (BNO) |
ISIN: | AU000000BNO5 |
Date of Listing: | 21 December 1999 |
Date of Delisting: | 28 August 2023 |
Stock Exchange Status:
This entity was delisted from the Australian Securities Exchange on 28 August 2023.Legal Status:
ACN: 075 582 740ABN: 53 075 582 740
Registration Date: 27 September 1996
Capital Gains Tax (CGT) Status:
To our knowledge this entity was delisted for reasons unrelated to either the takeover of its shares or the redemption of its securities. If you are seeking to crystallise a capital loss for tax purposes that process can be easily and quickly initiated at our online Worthless Shares facility here: https://www.delisted.com.au/sell-worthless-and-other-securities/. Any other enquiries relating to your securities should be followed up via our online form here: https://www.delisted.com.au/TraceLostSharesLostMoney/index/.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
REGISTRY:
Computershare Adelaide
Level 5, 115 Grenfell Street, Adelaide SA 5000
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 8 9473 2408 or 1300 534 987
RegistryWebsite RegistryEmail
The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares. | 06/11/2024 |
The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares. | 31/10/2024 |
The company has lodged financial reports with ASIC. | 15/10/2024 |
The company notifies ASIC of the appointment or cessation of a director or company secretary. | 10/10/2024 |
The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares. | 02/10/2024 |
The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares. | 14/08/2024 |
ASIC is notified of the resignation of the company's auditor. | 20/06/2024 |
The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares. | 17/06/2024 |
The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares. | 20/02/2024 |
The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares. | 19/02/2024 |
The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares. | 16/02/2024 |
The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares. | 09/02/2024 |
Company lodges a form with ASIC being a notification of the issue of shares. | 05/02/2024 |
The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares. | 05/02/2024 |
Company reports the following corporate highlights: In support of the Company's transformation into a commercial-stage company, expanded the U.S.-based team with new highly experienced management appointments, positioning it to become a leading company in neuropsychiatry. Voluntarily delisted from the Australian Stock Exchange in August 2023 and is currently solely listed on the NASDAQ Global Market. Further reduced cash burn through efficient capital allocation. Maintained its current institutional investors' support while adding new institutional investors to its register. Sustained strong analyst coverage that highlights the Company's potential future value. The Company has no outstanding debt, convertible securities, or warrants. Continued strengthening BNC210 intellectual property portfolio in the U.S. and abroad. | 22/01/2024 |
delisted at entity's request under Listing Rule 17.11 | 28/08/2023 |
we understand the company delisted because of low trading volumes on ASX, costs of the listing, leverage gained from the US institutional base, location of directors and management and the geographic location of the largest shareholders - Nasdaq is now its sole listing | 28/08/2023 |
The securities of Bionomics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of BNO, to facilitate its removal from the official list of ASX Limited. | 25/08/2023 |
shares reinstated to quotation | 08/09/2009 |
shares suspended from quotation following an announcement of an acquisition | 07/09/2009 |
The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares. | 06/11/2024 |
The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares. | 31/10/2024 |
The company has lodged financial reports with ASIC. | 15/10/2024 |
The company notifies ASIC of the appointment or cessation of a director or company secretary. | 10/10/2024 |
The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares. | 02/10/2024 |
The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares. | 14/08/2024 |
ASIC is notified of the resignation of the company's auditor. | 20/06/2024 |
The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares. | 17/06/2024 |
The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares. | 20/02/2024 |
The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares. | 19/02/2024 |
The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares. | 16/02/2024 |
The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares. | 09/02/2024 |
Company lodges a form with ASIC being a notification of the issue of shares. | 05/02/2024 |
The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares. | 05/02/2024 |
Company reports the following corporate highlights: In support of the Company's transformation into a commercial-stage company, expanded the U.S.-based team with new highly experienced management appointments, positioning it to become a leading company in neuropsychiatry. Voluntarily delisted from the Australian Stock Exchange in August 2023 and is currently solely listed on the NASDAQ Global Market. Further reduced cash burn through efficient capital allocation. Maintained its current institutional investors' support while adding new institutional investors to its register. Sustained strong analyst coverage that highlights the Company's potential future value. The Company has no outstanding debt, convertible securities, or warrants. Continued strengthening BNC210 intellectual property portfolio in the U.S. and abroad. | 22/01/2024 |
delisted at entity's request under Listing Rule 17.11 | 28/08/2023 |
we understand the company delisted because of low trading volumes on ASX, costs of the listing, leverage gained from the US institutional base, location of directors and management and the geographic location of the largest shareholders - Nasdaq is now its sole listing | 28/08/2023 |
The securities of Bionomics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of BNO, to facilitate its removal from the official list of ASX Limited. | 25/08/2023 |
shares reinstated to quotation | 08/09/2009 |
shares suspended from quotation following an announcement of an acquisition | 07/09/2009 |
Your browser may reflect a date of printing in American format.
DATE | DIRECTOR | NATURE | NUMBER | PRICE | AMOUNT |
---|---|---|---|---|---|
20/12/2021 | Alan Fisher | 100,000 | $0.120 | $12,000 | |
14/09/2016 | Peter Turner | 100,000 | $0.289 | $28,944 | |
01/09/2016 | Deborah Rathjen | On market | 100,000 | $0.247 | $24,735 |
12/08/2016 | David Ian Wilson | On market | 200,000 | $0.284 | $56,720 |
11/12/2015 | Deborah Rathjen | On market | 105,500 | $0.390 | $41,178 |
NAME | TITLE | DATE OF APPT |
---|---|---|
Alan Fisher | Non Exec Chairman | 31/08/2016 |
Tim Cunningham | CFO | 01/07/2023 |
Errol De Souza | Non Exec Director | 28/02/2008 |
Jane Ryan | Non Exec Director | 01/10/2020 |
David Ian Wilson | Non Exec Director | 16/06/2016 |
Miles Davies | Non Exec Director | 01/07/2021 |
Aaron Weaver | Non Exec Director | 06/07/2020 |
Suzanne Irwin | Company Secretary |
Date of first appointment, title may have changed.
NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
---|---|---|---|
Mitchell Kaye | Non Exec Director | 23/11/2018 | 31/12/2021 |
Srinivas Rao | Non Exec Director | 01/10/2020 | 01/07/2021 |
Peter Turner | Non Exec Director | 16/06/2016 | 20/11/2020 |
Stephen Birrell | Executive, CFO | 24/05/2017 | 31/05/2019 |
Deborah Rathjen | CEO | 18/05/2000 | 31/01/2019 |
Steven Lydeamore | CFO | 01/08/2017 | 23/11/2018 |
Melanie Young | CFO | 13/05/2011 | 24/05/2017 |
Trevor Tappenden | Non Exec Director | 18/09/2006 | 08/11/2016 |
Graeme Kaufman | Chairman | 18/09/2012 | 31/08/2016 |
Alan Dunton | Non Exec Director | 29/09/2015 | 04/07/2016 |
Jonathan Lim | Non Exec Director | 14/09/2012 | 18/11/2015 |
Chris Fullerton | Chairman | 23/12/2008 | 31/12/2012 |
Peter Jonson | Non Exec Chairman | 18/10/2004 | 04/11/2009 |
George Jessup | Non Exec Director | 01/07/2005 | 01/04/2008 |
Peter Maddern | Non Exec Director | 04/10/1996 | 30/06/2006 |
Christopher Henney | Non Exec Director | 28/02/1998 | 30/06/2006 |
George Morstyn | Non Exec Director | 08/08/2001 | 16/06/2006 |
Fraser Ainsworth | Chairman | 01/02/1999 | 01/11/2004 |
Warren Kinston | Non Exec Director | 08/11/2001 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2025 Investogain Pty Limited. All rights reserved.